Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan
Pharmacology Research & Perspectives · 2026-06 · 14 (3)
DOI: 10.1002/prp2.70271 ↗At a glance
Übersichtsarbeit in Pharmacology Research & Perspectives, published online on 2026-05-18. Written by Sola Akinbolade and 5 co-authors. Institution: National Institute for Health and Care Research (NIHR) Innovation Observatory, Population Health Sciences Institute, Faculty of Medical Sciences, New…. Major MEDLINE topics: Drug Repositioning, Antiviral Agents. 24 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research.
Abstract (original language)
Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to expand treatment options during public health emergencies. This scan aimed to map current investigational activity involving repurposed medicines for these viruses. A horizon scanning approach was employed, starting with a targeted search in Embase followed by a systematic search of ClinicalTrials.gov to identify developmental stages of relevant technologies. Eligible technologies included UK‐ or EU‐licensed medicines being investigated for antiviral use, while vaccines, unlicensed medicines, and treatments already approved for the target viruses were excluded. From the literature, 196 repurposed technologies were identified, and the expanded search on the clinical trials registry revealed 58 technologies in active clinical development. Interventional trial activity was limited to influenza and SARS‐CoV‐2, with 29 technologies for SARS‐CoV‐2 and two influenza technologies advancing to phase III evaluation. For other viruses, candidate repurposed technologies were identified only at preclinical or exploratory stages. Frequently investigated pharmacological classes included direct‐acting antivirals, immunomodulators, and anti‐inflammatory agents. While repurposing represents a potentially rapid strategy for therapeutic deployment, inclusion in this horizon scan does not imply clinical efficacy. Rigorous preclinical validation, pharmacokinetic feasibility assessment, and mechanistic confirmation remain essential before clinical translation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- National Institute for Health and Care Research (NIHR) Innovation Observatory, Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
ORCID profiles: Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman
Funding
- National Institute for Health and Care Research
Cite
APA
Akinbolade, S., Potter, R., Inskip, A., Nesworthy, J., Brock, K., & Norman, G. (2026). Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70271
Vancouver
Akinbolade S, Potter R, Inskip A, Nesworthy J, Brock K, Norman G. Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70271
BibTeX
@article{Akinbolade2026,
author = {Akinbolade, Sola and Potter, Rhiannon and Inskip, Alex and Nesworthy, Jane and Brock, Kirsti and Norman, Gill},
title = {Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {3},
doi = {10.1002/prp2.70271}
}
EUVIMED